Somewhat Favorable Press Coverage Somewhat Unlikely to Affect OvaScience (OVAS) Share Price

News stories about OvaScience (NASDAQ:OVAS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OvaScience earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.3427464066153 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of OvaScience (OVAS) traded up $0.12 on Thursday, hitting $1.47. The stock had a trading volume of 2,071,600 shares, compared to its average volume of 1,686,350. The stock has a market cap of $48.38, a price-to-earnings ratio of -0.80 and a beta of 3.73. OvaScience has a 12-month low of $1.25 and a 12-month high of $2.05.

Several analysts have recently commented on the company. Zacks Investment Research lowered OvaScience from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of OvaScience in a report on Monday, November 6th.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3125692/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-ovascience-ovas-share-price.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.